Dated: June 4, 2004.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 04–13133 Filed 6–9–04; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Institute for Occupational Safety and Health; Public Meeting

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the following public meeting and request for information:

Name: Public Meeting to Seek Input on Gaps in Chronic Lymphocytic Leukemia Radiogenicity Research.

Time and Date: 9 a.m.–12 noon, July 21, 2004.

Place: Best Western Skyline Inn, 10 I Street, SW., Washington, DC 20024.

Status: Forum will include scientists and representatives from various government agencies, industry, labor, and other stakeholders, and is open to the public, limited only by the space available. The meeting room accommodates up to 100 people. Due to limited space, notification of intent to attend the meeting should be made with Patty Gudlewski, no later than Friday, July 16, 2004. Ms. Gudlewski can be reached by telephone at 513–841–4419, or by e-mail at *pkg1@cdc.gov*. Access to the meeting will be accommodated on a first-come basis.

Purpose: To discuss possible scientific research strategies to evaluate any relationship between exposure to ionizing radiation and chronic lymphocytic leukemia (CLL). Current scientific opinion, based largely on epidemiological data, holds that the incidence of CLL is not related to exposure to ionizing radiation. The U.S. Congress directed NIOSH to conduct epidemiological research and other activities to establish the scientific link between radiation exposure and the occurrence of CLL.

The public is invited to attend and will have an opportunity to provide limited comments. Written comments may be submitted to the address listed below by August 16, 2004, so that they may be considered by NIOSH in planning its research priorities.

Summary: CLL is the most common adult leukemia in the Western world, but its etiology is largely unknown. Exposures to some herbicides have been implicated in epidemiologic studies. Yet other studies to date largely have shown no evidence of an association between external ionizing radiation and CLL; however, a number of uncertainties remain and additional studies may be informative. Recent laboratory studies have identified sub-types of CLL and at least one familial form of B-cell CLL has been identified. In addition, new technologies including interphase fluorescence *in situ* hybridization, expression microarrays and flow cytometric analysis provide diagnostic and prognostic indicators of disease. This meeting will assist in identifying gaps in existing research needed to address the radiogenicity of CLL.

Addresses: Comments should be submitted to David F. Utterback, 4676 Columbia Parkway, M/S R–44, Cincinnati, Ohio 45226, or by e-mail to *dutterback@cdc.gov*. Any attachments should be formatted in Microsoft Word.

All information received in response to this notice will be available for public examination and copying.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: June 4, 2004.

Alvin Hall,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 04–13134 Filed 6–9–04; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

Privacy Act of 1974; Report of New System

AGENCY: Department of Health and Human Services (HHS), Centers for Medicare & Medicaid Services (CMS).

ACTION: Notice of new system of records (SOR).

SUMMARY: In accordance with the requirements of the Privacy Act of 1974, we are proposing to establish a new SOR, titled ''MMA Section 641 Prescription Drug Benefit Demonstration'' (MMA641) System NO. 09–70–0545, HHS/CMS/ORDI. The primary purposes of the system of records are to maintain information on individual Medicare beneficiaries who voluntarily enroll in a demonstration project for coverage of certain prescription drugs and biologicals. This demonstration project is mandated in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 under section 641. The system of records will enable CMS to: Enroll and communicate with eligible Medicare beneficiaries who volunteer to participate in the demonstration project, communicate with clinicians and other providers and suppliers who submit claims payable under the demonstration project, review submitted claims and pay those conforming to applicable payment criteria and federal law, and develop, maintain, and analyze research information showing the potential impact of providing certain prescription drugs and biologicals.

Information retrieved from this system of records will also be disclosed to support regulatory, reimbursement, and policy functions performed within the agency or by a contractor or consultant; support constituent requests made to a Congressional representative; support litigation involving the agency; support activities reasonably necessary to fulfill the provisions of the demonstration project and ensure appropriate use of Medicare trust fund and program funds; and third parties where the contact is expected to have information relating to the individual's capacity to manage his or her own affairs.

We have provided background information about the proposed system in the ''Supplementary Information'' section, below. CMS invites comments on all portions of this notice. See ''Effective Dates'' section for comment period.

EFFECTIVE DATES: CMS filed a new system report with the Chair of the House Committee on Government Reform and Oversight, the Chair of the Senate Committee on Governmental Affairs, and the Administrator, Office of Information and Regulatory Affairs, Office of Management and Budget (OMB) on June 4, 2004. In any event, we will not disclose any information under a routine use until forty (40) calendar days after publication. We may defer implementation of this system of records or one or more of the routine use statements listed below if we receive comments that persuade us to defer implementation.

ADDRESSES: The public should address comments to: Director, Division of Privacy Compliance Data Development (DPCDD), CMS, Room N2–04–27, 7500 Security Boulevard, Baltimore, Maryland 21244–1850. Comments received will be available for review at this location, by appointment, during regular business hours, Monday through Friday from 9 a.m.–3 p.m., eastern time zone.

FOR FURTHER INFORMATION CONTACT: James Coan, Division of Health Promotion and Disease Prevention Demonstrations (DHPDPD), Office of Research, Development, and Information, CMS, MS–S3–02–01, 7500 Security Boulevard, Baltimore,